Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

详细信息    查看全文

• 作者：Kazuaki Matsumoto (1) (3)
  Yoshio Takesue (1) (4)
  Norio Ohmagari (1) (5)
  Takahiro Mochizuki (2) (6)
  Hiroshige Mikamo (1) (7)
  Masafumi Seki (1) (8)
  Shunji Takakura (1) (9)
  Issei Tokimatsu (1) (10)
  Yoshiko Takahashi (1) (11)
  Kei Kasahara (1) (12)
  Kenji Okada (13) (2)
  Masahiro Igarashi (14) (2)
  Masahiro Kobayashi (15) (2)
  Yukihiro Hamada (2) (7)
  Masao Kimura (16) (2)
  Yoshifumi Nishi (17) (2)
  Yusuke Tanigawara (18) (2)
  Toshimi Kimura (13) (2)
  
• 关键词：Guideline ; Vancomycin ; Therapeutic drug monitoring ; MRSA
• 刊名：Journal of Infection and Chemotherapy
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：19
• 期：3
• 页码：365-380
• 全文大小：288KB
• 参考文献：1. Geraci JE, Heilman FR, Nichols DR, Ross GT, Wellman WE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Proc Staff Meet Mayo Clin. 1956;31:564鈥?2.
  2. Geraci JE, Heilman FR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. Proc Staff Meet Mayo Clin. 1958;33:172鈥?1.
  3. Kirby WM, Perry DM, Bauer AW. Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases. N Engl J Med. 1960;262:49鈥?5. CrossRef
  4. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant / Staphylococcus aureus. Ann Intern Med. 1982;97:344鈥?0. CrossRef
  5. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42:S5鈥?2. CrossRef
  6. Rybak MJ, Bailey EM, Warbasse LH. Absence of 鈥渞ed man syndrome鈥?in patients being treated with vancomycin or high-dose teicoplanin. Antimicrob Agents Chemother. 1992;36:1204鈥?. CrossRef
  7. Bergman MM, Glew RH, Ebert TH. Acute interstitial nephritis associated with vancomycin therapy. Arch Intern Med. 1988;148:2139鈥?0. CrossRef
  8. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med. 1987;83:1091鈥?. CrossRef
  9. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25:679鈥?7. CrossRef
  10. Traber PG, Levine DP. Vancomycin ototoxicity in patient with normal renal function. Ann Intern Med. 1981;95:458鈥?0. CrossRef
  11. Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003;23:643鈥?0. CrossRef
  12. Cant煤 TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis. 1994;18:533鈥?3. CrossRef
  13. Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother. 1989;33:791鈥?. CrossRef
  14. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82鈥?8. CrossRef
  15. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18鈥?5. CrossRef
  16. Kobayashi M, Takesue Y, Tanigawara Y, Mikamo H, Kimura T, Hirata S, et al. Therapeutic drug monitoring survey of anti-MRSA agents in Japan. Jpn J Chemother. 2010;58:119鈥?4.
  17. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J. 1979;121:1193鈥?54.
  18. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010;123:1143鈥?. CrossRef
  19. Teramachi H, Hatakeyama H, Matsushita R, Imai Y, Miyamoto K, Tsuji A. Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters. Biol Pharm Bull. 2002;25:1333鈥?. CrossRef
  20. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann Pharmacother. 2011;45:757鈥?3. CrossRef
  21. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int. 2010;77:760鈥?. CrossRef
  22. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011;37:95鈥?01. CrossRef
  23. Niidome S, Kusano M, Karino M, Jingami S, Fukunaga E, Miyamura S, et al. Evaluation of various kidney functions equations for dose setting of vancomycin corrected by various parameters of physical constitutions. Jpn J Ther Drug Monit. 2011;28:92鈥?01.
  24. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with / Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925鈥?2. CrossRef
  25. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975鈥?1. CrossRef
  26. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet. 1994;344:1748鈥?0. CrossRef
  27. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009;53:483鈥?. CrossRef
  28. Winter ME. Basic principles. In: Winter ME, editor. Basic clinical pharmacokinetics. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. p. 2鈥?32.
  29. Rowland M, Tozer TN. Therapeutic regimens. In: Rowland M, Tozer TN, editors. Clinical pharmacokinetics and pharmacodynamics. Concepts and allocations. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2011. p. 245鈥?29.
  30. Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20:139鈥?8. CrossRef
  31. Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32:848鈥?2. CrossRef
  32. Takahashi Y, Takesue Y, Takubo S, Ishihara M, Nakajima K, Tsuchida T, et al. Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once daily administration of vancomycin. J Infect Chemother 2013 (Epub ahead of print).
  33. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can鈥檛 get there from here. Clin Infect Dis. 2011;52:969鈥?4. CrossRef
  34. Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens鈥?antibacterial susceptibility. J Infect Chemother. 2011;17:510鈥?3. CrossRef
  35. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:1536鈥?2. CrossRef
  36. Christiansen K, Currie B, Ferguson J, Franks G, Garland S, Grayson L, et al. Therapeutic guidelines: antibiotic. 14th ed. Melbourne: Therapeutic Guidelines Limited; 2010.
  37. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant / Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521鈥?. CrossRef
  38. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006;57:699鈥?04. CrossRef
  39. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate / Staphylococcus aureus. Clin Infect Dis. 2004;38:448鈥?1. CrossRef
  40. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507鈥?4. CrossRef
  41. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in methicillin-resistant / Staphylococcus aureus nosocomial pneumonia: a randomized controlled Study. Clin Infect Dis. 2012;54:621鈥?. CrossRef
  42. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant / Staphylococcus aureus pneumonia. Clin Ther. 2007;29:1107鈥?5. CrossRef
  43. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21:575鈥?0. CrossRef
  44. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52:1330鈥?. CrossRef
  45. Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. Clin Ther. 2012;34:1667鈥?3. CrossRef
  46. Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant / Staphylococcus aureus. Am J Surg. 2010;199:804鈥?6. CrossRef
  47. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by / Staphylococcus aureus. N Engl J Med. 2006;355:653鈥?5. CrossRef
  48. Leu WJ, Liu YC, Wang HW, Chien HY, Liu HP, Lin YM. Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients. Int J Infect Dis. 2012;16:e804鈥?0. CrossRef
  49. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008;62:168鈥?1. CrossRef
  50. Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009;34:570鈥?. CrossRef
  51. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, M眉ller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology. 2009;111:356鈥?5. CrossRef
  52. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:17鈥?4. CrossRef
  53. Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29:351鈥?. CrossRef
  54. Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and 鈥渞ed man syndrome鈥? comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother. 1990;34:550鈥?. CrossRef
  55. Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother. 1987;31:393鈥?. CrossRef
  56. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57:734鈥?4. CrossRef
  57. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med. 2010;123:182.e1鈥?.
  58. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138鈥?4. CrossRef
  59. Wang JT, Fang CT, Chen YC, Chang SC. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother. 2001;47:246. CrossRef
  60. Li J, Udy AA, Kirkpatrick CM, Lipman J, Roberts JA. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. Int J Antimicrob Agents. 2012;39:69鈥?2. CrossRef
  61. Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J. 2012;42:23鈥?. CrossRef
  62. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother. 2009;63:1050鈥?. CrossRef
  63. Soriano A, Marco F, Mart铆nez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant / Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193鈥?00. CrossRef
  64. Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2聽渭g/ml methicillin-resistant / Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother. 2011;17:52鈥?. CrossRef
  65. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in / Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755鈥?1. CrossRef
  66. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant / Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315鈥?0. CrossRef
  67. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant / Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007;51:2582鈥?. CrossRef
  68. Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC. Nosocomial methicillin-resistant / Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC聽=聽2聽mg/L, by the broth microdilution method. BMC Infect Dis. 2010;10:159. CrossRef
  69. Al贸s JI, Garc铆a-Ca帽as A, Garc铆a-Hierro P, Rodr铆guez-Salvan茅s F. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother. 2008;62:773鈥?. CrossRef
  70. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate / Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant / S. aureus (MRSA) blood isolates from 2001鈥?5. J Antimicrob Chemother. 2007;60:788鈥?4. CrossRef
  71. Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant / Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother. 2009;53:4127鈥?2.
  72. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant / Staphylococcus aureus strains. Clin Infect Dis. 2008;46(suppl 5):S360鈥?. CrossRef
  73. Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant / Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents. 2008;32:378鈥?5. CrossRef
  74. Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs for methicillin-resistant / Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother. 2008;52:4528. CrossRef
  75. Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant / Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:3162鈥?. CrossRef
  76. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, et al. Vancomycin-intermediate / Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by / Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997鈥?001. Clin Infect Dis. 2003;36:429鈥?9. CrossRef
  77. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for / Staphylococcus aureus. Clin Infect Dis. 2007;44:1208鈥?5. CrossRef
  78. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079鈥?2. CrossRef
  79. Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother. 2011;66:1057鈥?0. CrossRef
  80. Crompton JA, North DS, Yoon M, Steenbergen JN, Lamp KC, Forrest GN. Outcomes with daptomycin in the treatment of / Staphylococcus aureus infections with a range of vancomycin MICs. J Antimicrob Chemother. 2010;65:1784鈥?1. CrossRef
  81. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant / Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54:51鈥?. CrossRef
  82. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981;94:343鈥?. CrossRef
  83. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25:433鈥?. CrossRef
  84. Kullar R, Leonard SN, Davis SL, Delgado G Jr, Pogue JM, Wahby KA, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15鈥?0聽mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy. 2011;31:441鈥?. CrossRef
  85. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int. 1994;45:232鈥?. CrossRef
  86. Clark WR, Leypoldt JK, Henderson LW, Mueller BA, Scott MK, Vonesh EF. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol. 1999;10:601鈥?.
  87. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis. 1992;20:354鈥?0.
  88. B枚hler J, Reetze-Bonorden P, Keller E, Kramer A, Schollmeyer PJ. Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes. Eur J Clin Pharmacol. 1992;42:635鈥?. CrossRef
  89. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int. 1994;45:232鈥?. CrossRef
  90. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int. 1996;50:929鈥?6. CrossRef
  91. Brown M, Polisetty R, Gracely EJ, Cuhaci B, Schlecht HP. Weight-based loading of vancomycin in patients on hemodialysis. Clin Infect Dis. 2011;53:164鈥?. CrossRef
  92. Vandecasteele SJ, De Bacquer D, De Vriese AS. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15鈥?0聽microg/ml in persons undergoing hemodialysis. Clin Infect Dis. 2011;53:124鈥?. CrossRef
  93. Crawford BS, Largen RF, Walton T, Doran JJ. Once-weekly vancomycin for patients receiving high-flux hemodialysis. Am J Health Syst Pharm. 2008;65:1248鈥?3. CrossRef
  94. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance鈥搘hat鈥檚 dosing got to do with it? Crit Care Med. 2008;36:2433鈥?0. CrossRef
  95. Gatward JJ, Gibbon GJ, Wrathall G, Padkin A. Renal replacement therapy for acute renal failure: a survey of practice in adult intensive care units in the United Kingdom. Anaesthesia. 2008;63:959鈥?6. CrossRef
  96. RENAL Study Investigators. Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey. Crit Care Resusc. 2008;10:225鈥?0.
  97. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159鈥?6. CrossRef
  98. Joy MS, Matzke GR, Frye RF, Palevsky PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis. 1998;31:1019鈥?7. CrossRef
  99. Chaijamorn W, Jitsurong A, Wiwattanawongsa K, Wanakamanee U, Dandecha P. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents. 2011;38:152鈥?. CrossRef
  100. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. 2004;58:259鈥?8. CrossRef
  101. Yamamoto T, Yasuno N, Katada S, Hisaka A, Hanafusa N, Noiri E, et al. Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration. Antimicrob Agents Chemother. 2011;55:5804鈥?2. CrossRef
  102. Hirasawa H, Oda S, Nakamura M, Watanabe E, Shiga H, Matsuda K. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter for sepsis. Blood Purif. 2012;34:164鈥?0. CrossRef
  103. Morse GD, Farolino DF, Apicella MA, Walshe JJ. Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1987;31:173鈥?. CrossRef
  104. Wiggins KJ, Craig JC, Johnson DW, Strippoli GFM. Treatment for peritoneal dialysis-associated peritonitis. London: The Cochrane Library; 2010.
  105. Monta帽茅s Pauls B, Almi帽ana MA, Casab贸 Al贸s VG. Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis. Eur J Pharm Sci. 2011;43:212鈥?.
  106. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010;30:393鈥?23. CrossRef
  107. Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1983;34:631鈥?. CrossRef
  108. Manley HJ, Bailie GR, Frye RF, McGoldrick MD. Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int. 2001;21:378鈥?5.
  109. Broome L, So TY. An evaluation of initial vancomycin dosing in infants, children, and adolescents. Int J Pediatr. 2011 (Epub ahead of print).
  110. Kim DI, Im MS, Choi JH, Lee J, Choi EH, Lee HJ. Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients. Korean J Pediatr. 2010;53:1000鈥?. CrossRef
  111. Eiland LS, English TM, Eiland EH 3rd. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45:582鈥?. CrossRef
  112. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant / Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28:398鈥?02. CrossRef
  113. Glover ML, Cole E, Wolfsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care. 2000;15:1鈥?. CrossRef
  114. McCabe T, Davis G, Iocono J, Nelson C, Kuhn R. Evaluating the empiric dose of vancomycin in pediatric patients (abstract). J Pediatr Pharmacol Ther. 2009;14:168.
  115. Gordon CL, Thompson C, Carapetis JR, Turnidge J, Kilburn C, Currie BJ. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children. Pediatr Infect Dis J. 2012;31:1269鈥?1. CrossRef
  116. Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011;31:871鈥?. CrossRef
  
• 作者单位：Kazuaki Matsumoto (1) (3)
  Yoshio Takesue (1) (4)
  Norio Ohmagari (1) (5)
  Takahiro Mochizuki (2) (6)
  Hiroshige Mikamo (1) (7)
  Masafumi Seki (1) (8)
  Shunji Takakura (1) (9)
  Issei Tokimatsu (1) (10)
  Yoshiko Takahashi (1) (11)
  Kei Kasahara (1) (12)
  Kenji Okada (13) (2)
  Masahiro Igarashi (14) (2)
  Masahiro Kobayashi (15) (2)
  Yukihiro Hamada (2) (7)
  Masao Kimura (16) (2)
  Yoshifumi Nishi (17) (2)
  Yusuke Tanigawara (18) (2)
  Toshimi Kimura (13) (2)
  
  1. Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
  3. Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  4. Department of Infection Control and Prevention, Hyogo Medical College Hospital, Hyogo, Japan
  5. Disease Control and Prevention Center National Center for Global Health and Medicine Hospital, Tokyo, Japan
  2. Sectional Committee of Practice Guidelines for TDM, Antimicrobial Agents, The Japanese Society of Therapeutic Drug Monitoring, Niigata, Japan
  6. Department of Pharmacy, Shizuoka Cancer Center, Shizuoka, Japan
  7. Department of Infection Control and Prevention, Aichi Medical University Graduate School of Medicine, Aichi, Japan
  8. Division of Infection Control and Prevention, Osaka University Medical Hospital, Osaka, Japan
  9. Department of Infection Control and Prevention, Kyoto University Hospital, Kyoto, Japan
  10. Internal Medicine II, Oita University Faculty of Medicine, Oita, Japan
  11. Department of Pharmacy, Hyogo Medical College Hospital, Hyogo, Japan
  12. Center for Infectious Diseases, Nara Medical University, Nara, Japan
  13. Department of Pharmacy, Tokyo Women鈥檚 Medical University Hospital, Tokyo, Japan
  14. Department of Pharmacy, Toranomon Hospital, Tokyo, Japan
  15. Department of Pharmacy, Kitasato University Hospital, Kanagawa, Japan
  16. Department of Pharmacy, Aichi Medical University Hospital, Aichi, Japan
  17. Department of Pharmacy, Kyorin University School of Medicine, Tokyo, Japan
  18. Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan
  
• ISSN：1437-7780

文摘